Advisors Preferred’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Advisors Preferred’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,655	Closed	-$140K	–	249
2025 Q4	$140K	Buy	+1,655	New	+$132K	0.02%	181
2020 Q4	–	Sell	-819	Closed	-$45K	–	181
2020 Q3	$45K	Buy	+819	New	+$44.2K	0.01%	120
2017 Q2	–	Sell	-393	Closed	-$20	–	234
2017 Q1	$20	Buy	+393	New	+$19.5K	0.01%	170
2016 Q1	–	Sell	-411	Closed	-$22K	–	230
2015 Q4	$22K	Sell	411 -420	-51%	-$22.1K	0.01%	132
2015 Q3	$41K	Sell	831 -44,997	-98%	-$2.58M	0.04%	77
2015 Q2	$2.67M	Buy	45,828 +40,656	+786%	+$2.38M	1.5%	14
2015 Q1	$297K	Buy	5,172 +4,197	+430%	+$230K	0.16%	70
2014 Q4	$49.2K	Sell	975 -3,024	-76%	-$147K	0.02%	229
2014 Q3	$187K	Sell	3,999 -40,530	-91%	-$1.83M	0.12%	75
2014 Q2	$2.01M	Buy	44,529 +38,946	+698%	+$1.68M	1.02%	36
2014 Q1	$236K	Buy	5,583 +1,596	+40%	+$66.9K	0.11%	135
2013 Q4	$156K	Buy	+3,987	New	+$150K	0.09%	104

Other funds holding IHE

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Advisors Preferred's IHE Position: Q1 2026 in Review

Advisors Preferred sold out of iShares US Pharmaceuticals ETF (IHE) in Q1 2026, closing a stake of 1,655 shares — an estimated $140K sold.

Advisors Preferred first reported a position in IHE in Q4 2013 and held it in 12 quarters. The position peaked at $2.67M in Q2 2015. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

Advisors Preferred reported no remaining iShares US Pharmaceuticals ETF position as of Q1 2026 after selling out during the quarter.
Advisors Preferred sold 1,655 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $140K.
Advisors Preferred first reported a position in iShares US Pharmaceuticals ETF in Q4 2013 and held it in 12 quarters.
Advisors Preferred's iShares US Pharmaceuticals ETF position peaked at $2.67M in Q2 2015.
194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on Advisors Preferred's 13F filing for Q1 2026, filed 5 May 2026.